Breaking News Instant updates and real-time market news.

2021-01-19 20:40:08 DSS Document Security $5.48 / -0.47 (-7.90%) 20:40 01/19/21 01/19 20:40 01/19/21 20:40	Document Security 6.67M share Spot Secondary priced at $3.60 The deal priced below the last closing price of $5.50. Aegis is acting as sole book running manager for the offering.	21 Feb 22 May 02 Jul 28 Jul
DSS Document Security $5.48 / -0.47 (-7.90%) 06/24/20 Aegis Document Security assumed with a Buy at Aegis

2021-01-19 20:40:08

DSS

Document Security

$5.48 / -0.47 (-7.90%)

20:40

01/19/21

01/19

20:40

01/19/21

20:40

Document Security 6.67M share Spot Secondary priced at $3.60

The deal priced below the last closing price of $5.50. Aegis is acting as sole book running manager for the offering.

21
Feb
22
May
02
Jul
28
Jul

DSS Document Security

$5.48 / -0.47 (-7.90%)

06/24/20 Aegis: Document Security assumed with a Buy at Aegis

TODAY'S FREE FLY STORIES

Hot Stocks	Arbutus Biopharma sees cash runway into 3Q22 » 07:38 03/04/21 03/04 07:38 03/04/21 07:38 ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) Arbutus had cash, cash… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 02/26/21 Assembly Biosciences, Arbutus initiate Phase 2 trial of combination therapy 01/25/21 Arbutus Biopharma sees cash runway into mid-2022 01/25/21 Arbutus Biopharma announces 2021 corporate objectives 12/10/20 Arbutus Biopharma announces additional HBsAg decline data with AB-729 ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 12/17/20 H.C. Wainwright Arbutus Biopharma initiated with a Buy at H.C. Wainwright 09/15/20 Chardan Arbutus HBV data 'could represent a turning point,' says Chardan 07/27/20 B. Riley FBR Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR 07/24/20 Baird Arbutus Biopharma upside priced in, Baird downgrades to Neutral ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 07:38 Today Arbutus Biopharma reports 2020 EPS ($1.00), consensus (98c) 11/05/20 Arbutus Biopharma reports Q3 EPS (27c), consensus (22c) 08:45 Today Arbutus Biopharma - ABUS ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 12/15/20 Arbutus Biopharma call buyer realizes 80% same-day gains
Initiation	Histogen initiated with a Buy at Canaccord » 07:38 03/04/21 03/04 07:38 03/04/21 07:38 HSTO Histogen $1.15 / -0.035 (-2.95%) Canaccord Genuity analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Syndicate Options HSTO Histogen $1.15 / -0.035 (-2.95%) 02/16/21 Histogen announces Week 26 HST-001 study results 01/19/21 Histogen reports clinical hold on Phase 1/2 Trial of HST-003 for knee cartilage 12/17/20 Histogen files IND application for HST-003 12/01/20 Histogen announces preliminary week 18 HST-001 study results 31 Dec HSTO Histogen $1.15 / -0.035 (-2.95%) 01/19/21 Nine new option listings and thirteen option delistings on January 19th
Earnings	Arbutus Biopharma reports 2020 EPS ($1.00), consensus (98c) » 07:38 03/04/21 03/04 07:38 03/04/21 07:38 ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) Reports 2020 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 02/26/21 Assembly Biosciences, Arbutus initiate Phase 2 trial of combination therapy 01/25/21 Arbutus Biopharma sees cash runway into mid-2022 01/25/21 Arbutus Biopharma announces 2021 corporate objectives 12/10/20 Arbutus Biopharma announces additional HBsAg decline data with AB-729 ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 12/17/20 H.C. Wainwright Arbutus Biopharma initiated with a Buy at H.C. Wainwright 09/15/20 Chardan Arbutus HBV data 'could represent a turning point,' says Chardan 07/27/20 B. Riley FBR Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR 07/24/20 Baird Arbutus Biopharma upside priced in, Baird downgrades to Neutral ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 11/05/20 Arbutus Biopharma reports Q3 EPS (27c), consensus (22c) 08:45 Today Arbutus Biopharma - ABUS ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 12/15/20 Arbutus Biopharma call buyer realizes 80% same-day gains
Hot Stocks	Dicerna, Roche begin combo trial of GalXC for chronic HBV treatment » 07:37 03/04/21 03/04 07:37 03/04/21 07:37 DRNA Dicerna $29.00 / -0.52 (-1.76%) , RHHBY Roche $0.00 / + (+0.00%) Dicerna Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events DRNA RHHBY DRNA Dicerna $29.00 / -0.52 (-1.76%) 02/11/21 Dicerna initiates dosing in clinical trial of nedosiran for PH3 01/05/21 Dicerna announces first Novo Nordisk nominated candidate under agreement 01/04/21 Dicerna reports enrollment completion of PHYOX2 nedosiran trial 11/16/20 Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial RHHBY Roche $0.00 / + (+0.00%) 03/03/21 Adaptive says Genentech suspends development of shared antigen target candidate 02/26/21 Regeneron announces CHMP recommendation for COVID-19 antibody cocktail 02/24/21 Prothena announces presentation of new preclinical PRX005 data 02/19/21 Atea Pharmaceuticals announces Chugai in-license of AT-527 from Roche DRNA RHHBY DRNA Dicerna $29.00 / -0.52 (-1.76%) 03/02/21 H.C. Wainwright Dicerna price target raised to $40 from $35 at H.C. Wainwright 03/02/21 Chardan Dicerna price target raised to $34 from $25 at Chardan 03/01/21 B. Riley Securities Dicerna price target raised to $40 from $37 at B. Riley Securities 01/11/21 B. Riley Securities Dicerna price target raised to $37 from $30 at B. Riley Securities RHHBY Roche $0.00 / + (+0.00%) 03/03/21 Goldman Sachs Adaptive Biotechnologies downgraded to Neutral from Buy at Goldman Sachs 02/25/21 Berenberg Roche price target lowered to CHF 320 from CHF 325 at Berenberg 02/24/21 Morgan Stanley Roche price target lowered to CHF 345 from CHF 365 at Morgan Stanley 02/23/21 BofA BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list DRNA RHHBY DRNA Dicerna $29.00 / -0.52 (-1.76%) 02/25/21 Dicerna reports FY20 EPS ($1.52), consensus ($1.05) 11/05/20 Dicerna reports Q3 EPS (29c), consensus (20c) RHHBY Roche $0.00 / + (+0.00%) 02/04/21 Roche reports 2020 core EPS CHF 19.16 vs. CHF 20.16 last year 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year RHHBY RHHBY Roche $0.00 / + (+0.00%) 02/11/21 Roche arthritis drug reduced Covid deaths in study, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports DRNA RHHBY DRNA Dicerna $29.00 / -0.52 (-1.76%) 02/25/21 Fly Intel: After-Hours Movers RHHBY Roche $0.00 / + (+0.00%) 12/26/20 Week in review: How Trump's policies moved stocks 11/30/20 Fly Intel: Wall Street's top stories for Monday 11/30/20 Fly Intel: Wall Street's top stories at midday 11/21/20 Week in review: How Trump's policies moved stocks 03/25/21 Roche - RHHBY
Upgrade	Agricultural Bank of China upgraded to Buy from Neutral at Goldman Sachs » 07:37 03/04/21 03/04 07:37 03/04/21 07:37 ACGBY Agricultural Bank of China $0.00 / + (+0.00%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research ACGBY Agricultural Bank of China $0.00 / + (+0.00%) 04/03/20 Jefferies Agricultural Bank of China initiated with a Buy at Jefferies

Hot Stocks	Verrica Pharmaceuticals expects cash to support operations at least into 1Q22 » 07:36 03/04/21 03/04 07:36 03/04/21 07:36 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) As of December 31, 2020,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 07:35 Today Verrica says Torii exercises option to acquire license for VP-102 07:34 Today Verrica Pharmaceuticals resubmits NDA for VP-102 02/17/21 Verrica announces acceptance of resubmitted NDA filing for VP-102 01/19/21 Verrica Pharmaceuticals presents data from clinical studies of VP-102 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 12/24/20 Cowen Verrica approval for molluscum likely in Q3 of 2021, says Cowen 12/24/20 H.C. Wainwright Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright 07/15/20 BofA Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA 06/30/20 H.C. Wainwright Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 07:33 Today Verrica Pharmaceuticals reporrts Q4 EPS (52c), consensus (42c) 11/09/20 Verrica Pharmaceuticals reports Q3 EPS (42c), consensus (43c) 06/23/21 PDFUA Date for VP-102 Resubmission
Upgrade	Canaccord upgrades Okta to Buy on recent selloff, accretive acquisition » 07:36 03/04/21 03/04 07:36 03/04/21 07:36 OKTA Okta $242.42 / -16.595 (-6.41%) Canaccord analyst T.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options OKTA Okta $242.42 / -16.595 (-6.41%) 03/03/21 Okta drops 13% to $210.50 after Q1, FY22 profit view miss estimates 03/03/21 Okta to acquire Auth0 in deal valued at roughly $6.5B 12/02/20 Okta jumps 6.8% to $246 after Q3 results, FY21 guidance, AWS availability 12/02/20 Okta announces availability of Identity Cloud in AWS Marketplace OKTA Okta $242.42 / -16.595 (-6.41%) 06:53 Today Deutsche Bank Okta price target lowered to $270 from $313 at Deutsche Bank 06:45 Today Mizuho Okta price target lowered to $255 from $305 at Mizuho 06:37 Today Baird Okta price target lowered to $240 from $275 at Baird 06:06 Today Piper Sandler Okta price target lowered to $235 from $250 at Piper Sandler OKTA Okta $242.42 / -16.595 (-6.41%) 03/03/21 Okta sees FY22 adjusted EPS (49c)-(44c), consensus 1c 03/03/21 Okta sees Q1 adjusted EPS (21c)-(20c), consensus (7c) 03/03/21 Okta reports Q4 adjusted EPS 6c, consensus (1c) 03/03/21 Notable companies reporting after market close OKTA Okta $242.42 / -16.595 (-6.41%) 03/03/21 Fly Intel: After-Hours Movers 12/21/20 Analysts move to sidelines on SolarWinds following cyberattack 12/09/20 JPMorgan downgrades Zoom, upgrades Autodesk in software ratings shakeup 12/02/20 Fly Intel: After-Hours Movers OKTA Okta $242.42 / -16.595 (-6.41%) 12/02/20 Okta options imply 9.8% move in share price post-earnings
Hot Stocks	Verrica says Torii exercises option to acquire license for VP-102 » 07:35 03/04/21 03/04 07:35 03/04/21 07:35 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) On March 2, Torii… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 07:34 Today Verrica Pharmaceuticals resubmits NDA for VP-102 02/17/21 Verrica announces acceptance of resubmitted NDA filing for VP-102 01/19/21 Verrica Pharmaceuticals presents data from clinical studies of VP-102 12/23/20 Verrica Pharmaceuticals resubmits VP-102 NDA VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 12/24/20 Cowen Verrica approval for molluscum likely in Q3 of 2021, says Cowen 12/24/20 H.C. Wainwright Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright 07/15/20 BofA Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA 06/30/20 H.C. Wainwright Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 07:33 Today Verrica Pharmaceuticals reporrts Q4 EPS (52c), consensus (42c) 11/09/20 Verrica Pharmaceuticals reports Q3 EPS (42c), consensus (43c) 06/23/21 PDFUA Date for VP-102 Resubmission
Upgrade	Postal Savings Bank of China upgraded to Conviction Buy at Goldman Sachs » 07:34 03/04/21 03/04 07:34 03/04/21 07:34 PSTVY Postal Savings Bank of China $0.00 / + (+0.00%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Hot Stocks	Verrica Pharmaceuticals resubmits NDA for VP-102 » 07:34 03/04/21 03/04 07:34 03/04/21 07:34 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) The Company recently… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 02/17/21 Verrica announces acceptance of resubmitted NDA filing for VP-102 01/19/21 Verrica Pharmaceuticals presents data from clinical studies of VP-102 12/23/20 Verrica Pharmaceuticals resubmits VP-102 NDA 11/17/20 Verrica Pharmaceuticals expects to resubmit VP-102 NDA in 1Q21 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 12/24/20 Cowen Verrica approval for molluscum likely in Q3 of 2021, says Cowen 12/24/20 H.C. Wainwright Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright 07/15/20 BofA Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA 06/30/20 H.C. Wainwright Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 07:33 Today Verrica Pharmaceuticals reporrts Q4 EPS (52c), consensus (42c) 11/09/20 Verrica Pharmaceuticals reports Q3 EPS (42c), consensus (43c) 06/23/21 PDFUA Date for VP-102 Resubmission

Earnings	Syros Pharmaceuticals reports Q4 EPS (62c), consensus (50c) » 07:33 03/04/21 03/04 07:33 03/04/21 07:33 SYRS Syros Pharmaceuticals $8.33 / -0.87 (-9.46%) Reports Q4 revenue $5.7M,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events SYRS Syros Pharmaceuticals $8.33 / -0.87 (-9.46%) 12/06/20 Syros acquires clinical-stage drug candidate for Acute Promyelocytic Leukemia 12/06/20 Syros Pharmaceuticals presents new data from Phase 2 trial of SY-1425 11/04/20 Syros to present new data from Phase 2 SY-1425 trial at ASH meeting 10/25/20 Syros presents initial data from Phase 1 trial of SY-5609 SYRS Syros Pharmaceuticals $8.33 / -0.87 (-9.46%) 11/10/20 Brookline Syros Pharmaceuticals initiated with a Buy at Brookline 11/05/20 Roth Capital Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital 11/04/20 Fly Intel: Top five analyst upgrades 11/04/20 H.C. Wainwright Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright SYRS Syros Pharmaceuticals $8.33 / -0.87 (-9.46%) 11/05/20 Syros Pharmaceuticals reports Q3 EPS (43c), consensus (38c) 20 Jan SYRS Syros Pharmaceuticals $8.33 / -0.87 (-9.46%) 01/19/21 Fly Intel: After-Hours Movers 01/07/21 Fly Intel: After-Hours Movers 08:30 Today Syros Pharmaceuticals - SYRS
General news	Challenger Job-Cut Report Level data reported » 07:33 03/04/21 03/04 07:33 03/04/21 07:33 February Challenger… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Earnings	Verrica Pharmaceuticals reporrts Q4 EPS (52c), consensus (42c) » 07:33 03/04/21 03/04 07:33 03/04/21 07:33 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) "Over the past year,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 02/17/21 Verrica announces acceptance of resubmitted NDA filing for VP-102 01/19/21 Verrica Pharmaceuticals presents data from clinical studies of VP-102 12/23/20 Verrica Pharmaceuticals resubmits VP-102 NDA 11/17/20 Verrica Pharmaceuticals expects to resubmit VP-102 NDA in 1Q21 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 12/24/20 Cowen Verrica approval for molluscum likely in Q3 of 2021, says Cowen 12/24/20 H.C. Wainwright Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright 07/15/20 BofA Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA 06/30/20 H.C. Wainwright Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 11/09/20 Verrica Pharmaceuticals reports Q3 EPS (42c), consensus (43c) 06/23/21 PDFUA Date for VP-102 Resubmission
Downgrade	Yext downgraded to Market Perform on growth headwinds at William Blair » 07:32 03/04/21 03/04 07:32 03/04/21 07:32 YEXT Yext $16.55 / -1.16 (-6.55%) William Blair analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events YEXT Yext $16.55 / -1.16 (-6.55%) 03/03/21 Yext drops 13% to $14.29 after Q4 results, FY22 guidance 02/23/21 Yext COO sells 80K shares of common stock 02/08/21 Yext names David Rudnitsky as President and Chief Revenue Officer 02/03/21 Yext and Carahsoft partner to develop search technology for public sector YEXT Yext $16.55 / -1.16 (-6.55%) 05:36 Today William Blair Yext downgraded to Market Perform from Outperform at William Blair 12/04/20 DA Davidson Yext price target lowered to $20.50 from $22 at DA Davidson 12/04/20 Truist Yext growth should pick up next year, says Truist 07/09/20 Needham Yext price target raised to $21 from $19 at Needham YEXT Yext $16.55 / -1.16 (-6.55%) 03/03/21 Yext sees Q1 non-GAAP EPS (7c)-(5c), consensus (6c) 03/03/21 Yext sees FY22 non-GAAP EPS (22c)-(17c) , consensus (27c) 03/03/21 Yext reports Q4 non-GAAP EPS 0c, consensus (8c) 12/03/20 Yext sees Q4 adjusted EPS (10c)-(8c), consensus (8c) YEXT Yext $16.55 / -1.16 (-6.55%) 03/03/21 Fly Intel: After-Hours Movers 12/04/20 Fly Intel: Wall Street's top stories for Friday 12/04/20 Fly Intel: Wall Street's top stories at midday 12/03/20 Fly Intel: After-Hours Movers 03/23/21 Yext
Hot Stocks	DraftKings becomes 'Official Sportsbook, Daily Fantasy Partner' of UFC » 07:32 03/04/21 03/04 07:32 03/04/21 07:32 DKNG DraftKings $65.75 / -2.785 (-4.06%) DraftKings will become… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options DKNG DraftKings $65.75 / -2.785 (-4.06%) 03/03/21 Dish, DraftKings announce strategic agreement 02/26/21 DraftKings MUPs for B2C segment up 44% vs. 4Q19 02/25/21 Bill introduced in Florida Senate to authorize sports wagering 02/25/21 Nevada reports January statewide gaming win down 26.6% to $761.85M DKNG DraftKings $65.75 / -2.785 (-4.06%) 03/01/21 Craig-Hallum DraftKings price target raised to $70 from $65 at Craig-Hallum 03/01/21 Canaccord DraftKings price target raised to $80 from $65 at Canaccord 03/01/21 Northland DraftKings price target raised to $70 from $55 at Northland 03/01/21 Benchmark DraftKings price target raised to $69 from $66 at Benchmark DKNG DraftKings $65.75 / -2.785 (-4.06%) 02/26/21 DraftKings raises 2021 revenue view to $900M-$1B from $750M-$850M 02/26/21 DraftKings reports Q4 revenue $322M, consensus $232.6M 02/25/21 Notable companies reporting before tomorrow's open 02/25/21 Notable companies reporting before tomorrow's open 07 Oct 19 Jun DKNG DraftKings $65.75 / -2.785 (-4.06%) 03/02/21 Hedgeye adds DraftKings as a Best Idea Short 03/02/21 Connecticut, Mohegan Tribe reach deal on sports betting, The Day reports 02/12/21 Nevada to roll back capacity restrictions on casinos, Reno Gazette Journal says 02/09/21 TX Lt. Gov. sees no support for legalized sports betting, Houston Chronicle says DKNG DraftKings $65.75 / -2.785 (-4.06%) 03/01/21 Fly Intel: Wall Street's top stories for Monday 02/26/21 Fly Intel: Wall Street's top stories for Friday 02/26/21 Bet On It: Florida and Texas trying to get in on the action 02/26/21 Fly Intel: Wall Street's top stories at midday 03/09/21 DraftKings Inc DKNG DraftKings $65.75 / -2.785 (-4.06%) 02/02/21 DraftKings call volume above normal and directionally bullish 01/27/21 DraftKings call volume above normal and directionally bullish 01/26/21 DraftKings call volume above normal and directionally bullish 01/12/21 DraftKings call volume above normal and directionally bullish

Hot Stocks	CureVac and Novartis in initial pact on Covid vaccine candidate » 07:31 03/04/21 03/04 07:31 03/04/21 07:31 CVAC CureVac $83.44 / -9.76 (-10.47%) , NVS Novartis $84.16 / -0.635 (-0.75%) CureVac (CVAC) and… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 02/05/21 CureVac enters pact with UK Government to develop SARS-CoV-2 variant vaccine 02/04/21 CureVac expands CV8102 cancer program to advanced melanoma 02/03/21 CureVac, GSK in pact to jointly develop mRNA vaccines for COVID-19 01/07/21 Bayer signs collaboration, services agreement with CureVac for COVID-19 vaccine NVS Novartis $84.16 / -0.635 (-0.75%) 03/02/21 Novartis shareholders approve 1.7% increase in dividend to CHF 3.00 per share 03/01/21 Homology Medicines regains worldwide rights to ophthalmology program 02/17/21 Novartis announces SCD grant agreement with Bill & Melinda Gates Foundation 02/16/21 Novartis reports Entresto granted expanded indication in chronic heart failure CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 01/07/21 Morgan Stanley CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley 12/10/20 Credit Suisse CureVac downgraded to Underperform on rising valuation at Credit Suisse 12/10/20 Credit Suisse CureVac downgraded to Underperform from Neutral at Credit Suisse 11/02/20 Piper Sandler CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper NVS Novartis $84.16 / -0.635 (-0.75%) 03/01/21 Oppenheimer Homology Medicines loses potential source of upside, says Oppenheimer 02/02/21 Morgan Stanley Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley 02/01/21 Truist iRhythm price target lowered to $220 from $265 at Truist 02/01/21 Cowen Novartis downgraded to Market Perform after 'tepid' guidance at Cowen NVS NVS Novartis $84.16 / -0.635 (-0.75%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook 28 Jan 14 Aug CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 01/06/21 CureVac, Bayer reach alliance deal over COVID-19 vaccine, Reuters says 09/04/20 Germany awards grant to CureVac to accelerate vaccine development, BI reports NVS Novartis $84.16 / -0.635 (-0.75%) 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 01/25/21 Fly Intel: After-Hours Movers 01/07/21 Fly Intel: Pre-market Movers 11/10/20 Fly Intel: Pre-market Movers 11/02/20 Fly Intel: Pre-market Movers NVS Novartis $84.16 / -0.635 (-0.75%) 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers 12/26/20 Week in review: How Trump's policies moved stocks CVAC CVAC CureVac $83.44 / -9.76 (-10.47%) 12/03/20 Largest borrow rate increases among liquid names 09/29/20 Largest borrow rate increases among liquid names 09/15/20 Largest borrow rate increases among liquid names 09/11/20 Largest borrow rate increases among liquid names
Hot Stocks	Dyne Therapeutics appoints Wildon Farwell as CMO » 07:30 03/04/21 03/04 07:30 03/04/21 07:30 DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) , BIIB Biogen $266.84 / -3.2 (-1.19%) Dyne Therapeutics (DYN)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 02/08/21 Dyne Therapeutics appoints Ashish Dugar as SVP, global head of medical affairs 01/10/21 Dyne Therapeutics announced new preclinical data from DM1 program 09/28/20 Citadel Advisors takes 6.5% passive stake in Dyne Therapeutics BIIB Biogen $266.84 / -3.2 (-1.19%) 02/03/21 Biogen sees FY21 adjusted R&D expense $2.35B-$2.45B 02/03/21 Biogen CEO sees 'a financial reset in 2021' 02/01/21 Biogen announces FDA approval of PLEGRIDY intramuscular administration 01/29/21 Biogen, Eisai announce 3-month extension of review period for aducanumab BLA DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 02/09/21 Dyne Therapeutics initiated with a Buy at JonesTrading 01/07/21 Piper Sandler Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper 10/12/20 Jefferies Dyne Therapeutics initiated with a Buy at Jefferies 10/12/20 JPMorgan Dyne Therapeutics initiated with an Overweight at JPMorgan BIIB Biogen $266.84 / -3.2 (-1.19%) 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald 02/08/21 Citi Expert sees Biogen aducanumab approval 50/50 at best, says Citi 02/04/21 SVB Leerink Biogen price target lowered to $380 from $430 at SVB Leerink 02/04/21 Credit Suisse Biogen price target lowered to $338 from $350 at Credit Suisse DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 11/05/20 Dyne Therapeutics reports Q3 EPS ($2.01), consensus (87c) BIIB Biogen $266.84 / -3.2 (-1.19%) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open 02/02/21 Notable companies reporting before tomorrow's open 21 Jan 17 Sep BIIB BIIB Biogen $266.84 / -3.2 (-1.19%) 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 01/21/21 Fly Intel: Wall Street's top stories for Thursday 01/21/21 Fly Intel: Wall Street's top stories at midday 09/28/20 Fly Intel: After-Hours Movers 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever BIIB Biogen $266.84 / -3.2 (-1.19%) 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 01/29/21 Fly Intel: Wall Street's top stories for Friday 03/08/21 Biopharmaceuticals 06/07/21 PDUFA Date for Aducanumab BIIB BIIB Biogen $266.84 / -3.2 (-1.19%) 09/15/20 Alexion strength attributed to takeover speculation BIIB BIIB Biogen $266.84 / -3.2 (-1.19%) 01/29/21 Early notable gainers among liquid option names on January 29th 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th
Downgrade	Regency Centers downgraded to Hold from Buy at Argus » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 REG Regency Centers $56.67 / +2.525 (+4.66%) Argus analyst Angus… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options REG Regency Centers $56.67 / +2.525 (+4.66%) 03/02/21 PS Business Parks appoints Dan Chandler as CEO 03/02/21 Regency Centers chief investment officer Mac Chandler to resign 01/27/21 Regency Centers issues TCFD Climate Change Risk Report 01/19/21 Regency Centers sold five shopping centers in Q4 for $77.8M REG Regency Centers $56.67 / +2.525 (+4.66%) 07:27 Today Argus Regency Centers downgraded to Hold from Buy at Argus 01/25/21 Compass Point Regency Centers upgraded to Buy from Neutral at Compass Point 12/30/20 Truist Regency Centers price target raised to $50 from $45 at Truist 08/19/20 Fly Intel: Top five analyst downgrades REG Regency Centers $56.67 / +2.525 (+4.66%) 02/11/21 Regency Centers sees FY21 FFO $2.96-$3.14, consensus $3.31 02/11/21 Regency Centers reports Q4 FFO 76c, consensus 72c 11/05/20 Regency Centers reports Q3 EPS 7c, consensus 21c REG Regency Centers $56.67 / +2.525 (+4.66%) 12/29/20 Early notable gainers among liquid option names on December 29th
Initiation	Open Lending initiated with an Outperform at William Blair » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 LPRO Open Lending $38.72 / -1.3 (-3.25%) William Blair analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate Events Options LPRO Open Lending $38.72 / -1.3 (-3.25%) 01/12/21 Open Lending signs Royal Credit Union to Lenders Protection Program 12/16/20 Open Lending signs Members 1st Federal Credit Union to lenders protection 09/14/20 Open Lending signs Sound Credit Union to Lenders Protection Program LPRO Open Lending $38.72 / -1.3 (-3.25%) 02/10/21 Needham Open Lending initiated with a Buy at Needham 01/20/21 DA Davidson Open Lending price target raised to $45 from $31 at DA Davidson 01/04/21 Deutsche Bank Open Lending named 'Catalyst Call: Buy Idea' at Deutsche Bank 01/04/21 Stephens Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens 10 Dec 03/09/21 Open Lending - LPRO LPRO Open Lending $38.72 / -1.3 (-3.25%) 10/07/20 Five new option listings on October 7th
Hot Stocks	Hookipa Pharma announces publication on alternating 2-vector cancer therapeutics » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) HOOKIPA Pharma announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 12/07/20 Hookipa Pharma reports 'positive' interim Phase 1 data on HB-201 11/30/20 Hookipa Pharma announces Phase 2 interim safety, efficacy results for HB-101 10/29/20 Hookipa Pharma doses first patient in Phase 1/2 trial for HB-202/HB-201 therapy 10/19/20 Hookipa Pharma appoints Jean-Charles Soria to board of directors HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 11/30/20 JMP Securities Hookipa Pharma price target raised to $25 from $19 at JMP Securities 11/03/20 Fly Intel: Top five analyst initiations 11/03/20 Truist Hookipa Pharma initiated with a Buy at Truist 11/03/20 Truist Hookipa Pharma initiated with a Buy at Truist HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 11/12/20 Hookipa Pharma reports Q3 EPS (53c), consensus (43c) 09 Dec HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 12/08/20 Fly Intel: After-Hours Movers 03/15/21 Hookipa Pharma - HOOK

Upgrade	Williams upgraded to Outperform from Sector Perform at Scotiabank » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 WMB Williams $23.73 / +0.02 (+0.08%) Scotiabank analyst Alonso… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options WMB Williams $23.73 / +0.02 (+0.08%) 01/26/21 Williams raises quarterly dividend to 41c from 40c 12/17/20 Williams' resolution with Chesapeake receives bankruptcy court approval 11/23/20 Williams announces global resolution with Chesapeake WMB Williams $23.73 / +0.02 (+0.08%) 02/24/21 Mizuho Williams price target raised to $27 from $26 at Mizuho 01/20/21 Mizuho Williams price target raised to $26 from $24 at Mizuho 12/17/20 Credit Suisse Williams upgraded to Outperform from Neutral at Credit Suisse 12/11/20 Morgan Stanley Morgan Stanley upgrades midstream industry view to Attractive, shakes up ratings WMB Williams $23.73 / +0.02 (+0.08%) 02/22/21 Williams sees FY21 adjusted EBITDA of $5.05B-$5.35B 02/22/21 Williams reports Q4 adjusted EPS 31c, consensus 31c 11/02/20 Williams sees 2020 Adjusted EBITDA in lower half of guidance range 11/02/20 Williams reports Q3 adjusted EPS 27c, consensus 27c WMB Williams $23.73 / +0.02 (+0.08%) 10/14/20 Fly Intel: After-Hours Movers WMB Williams $23.73 / +0.02 (+0.08%) 10/09/20 Williams call volume above normal and directionally bullish 10/07/20 Williams put volume heavy and directionally bearish 10/05/20 Unusually active option classes on open October 5th
Hot Stocks	Landos Biopharma says all endpoints in Phase 1 study of NX-13 met » 07:28 03/04/21 03/04 07:28 03/04/21 07:28 LABP Landos Biopharma $15.22 / +0.73 (+5.04%) Landos Biopharma… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly LABP Landos Biopharma $15.22 / +0.73 (+5.04%) 02/08/21 Landos Biopharma jumps 16% after disclosing insider buys 01/04/21 Landos Biopharma announces results from Phase 2 trial of BT-11 LABP Landos Biopharma $15.22 / +0.73 (+5.04%) 03/01/21 Jefferies Landos Biopharma initiated with a Buy at Jefferies 03/01/21 JPMorgan Landos Biopharma initiated with a Neutral at JPMorgan 03/01/21 Raymond James Landos Biopharma initiated with an Outperform at Raymond James 03/01/21 SVB Leerink Landos Biopharma initiated with an Outperform at SVB Leerink 04 Feb LABP Landos Biopharma $15.22 / +0.73 (+5.04%) 02/07/21 Opening Day: Sana raises largest-ever IPO for preclinical biotech
Downgrade	Regency Centers downgraded to Hold from Buy at Argus » 07:27 03/04/21 03/04 07:27 03/04/21 07:27 REG Regency Centers $56.67 / +2.525 (+4.66%) Argus analyst Jacob… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options REG Regency Centers $56.67 / +2.525 (+4.66%) 03/02/21 PS Business Parks appoints Dan Chandler as CEO 03/02/21 Regency Centers chief investment officer Mac Chandler to resign 01/27/21 Regency Centers issues TCFD Climate Change Risk Report 01/19/21 Regency Centers sold five shopping centers in Q4 for $77.8M REG Regency Centers $56.67 / +2.525 (+4.66%) 01/25/21 Compass Point Regency Centers upgraded to Buy from Neutral at Compass Point 12/30/20 Truist Regency Centers price target raised to $50 from $45 at Truist 08/19/20 Fly Intel: Top five analyst downgrades 08/19/20 Compass Point Compass Point downgrades Regency Centers on 'tactical valuation call' REG Regency Centers $56.67 / +2.525 (+4.66%) 02/11/21 Regency Centers sees FY21 FFO $2.96-$3.14, consensus $3.31 02/11/21 Regency Centers reports Q4 FFO 76c, consensus 72c 11/05/20 Regency Centers reports Q3 EPS 7c, consensus 21c REG Regency Centers $56.67 / +2.525 (+4.66%) 12/29/20 Early notable gainers among liquid option names on December 29th
Hot Stocks	NewAge enters LOI to acquire Japan-based Aliven for approx. 1M shares » 07:26 03/04/21 03/04 07:26 03/04/21 07:26 NBEV NewAge $2.82 / -0.1 (-3.43%) NewAge announced that it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events NBEV NewAge $2.82 / -0.1 (-3.43%) 02/16/21 NewAge announces $58M private placement 12/01/20 NewAge announces $30M debt facility 11/19/20 NewAge appoints Fred Cooper to board of directors 10/15/20 NewAge's DSD Division on track for double-digit organic growth in 2020 NBEV NewAge $2.82 / -0.1 (-3.43%) 07/21/20 Alliance Global Partners New Age Beverages price target raised to $5 from $3.50 at Alliance Global 04/14/20 Alliance Global Partners New Age Beverages at Alliance Global Partners 03/11/20 Compass Point New Age Beverages price target lowered to $4 from $9 at Compass Point NBEV NewAge $2.82 / -0.1 (-3.43%) 02/16/21 NewAge ses Q4 net revenue in $90M range, consensus $79.34M 11/09/20 NewAge reports Q3 EPS (14c), consensus (6c) NBEV NewAge $2.82 / -0.1 (-3.43%) 11/09/20 Fly Intel: Pre-market Movers 03/15/21 33rd Annual Roth Virtual Conference 03/16/21 NewAge - NBEV
Recommendations	Main Street price target raised to $40 from $34 at RBC Capital » 07:25 03/04/21 03/04 07:25 03/04/21 07:25 MAIN Main Street $37.33 / +0.63 (+1.72%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings MAIN Main Street $37.33 / +0.63 (+1.72%) 01/20/21 Main Street reports Q4 private loan activity 01/19/21 Capital Southwest supports O2's investment in Flip Electronics 01/07/21 Main Street announces new portfolio investment MAIN Main Street $37.33 / +0.63 (+1.72%) 08/12/20 Truist Main Street price target raised to $33 from $28 at Truist 04/15/20 National Securities Main Street downgraded to Neutral from Buy at National Securities 03/17/20 National Securities Main Street upgraded to Buy from Neutral at National Securities MAIN Main Street $37.33 / +0.63 (+1.72%) 02/25/21 Main Street reports Q4 NII 59c, consensus 51c 11/05/20 Main Street reports Q3 NII 46c, consensus 47c

Events

Earnings calls, analyst events, roadshows and more

BALY
Today at 08:00

Bally's - BALY Conference Calls
ATC
Today at 08:00

Atotech - ATC Conference Calls
WVE
Today at 08:00

Wave Life Sciences - WVE Conference Calls
FULC
Today at 08:00

Fulcrum Therapeutics - FULC Conference Calls
HCM
Today at 08:00

Hutchison China MediTech - HCM Conference Calls
Today at 08:00

Consumer Data Analytics Industry Meetings
Today at 08:30

Productivity & Costs: Non-farm Poductivity Annual Rate: Q4(r):2020 Government Event
Today at 08:30

Productivity and Costs: Unit Labor Costs Annual Rate: Q4(r):2020 Government Event
Today at 08:30

Initial Jobless Claims Level: Week 2/27/2021 Government Event
Today at 08:30

Initial Jobless Claims Change: Week 2/27/2021 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB Priced at: $39.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler Priced at: $4.00 15M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James Priced at: $130.00 3.85M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler Priced at: $186.00 941K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan Priced at: $60.00 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital Priced at: $70.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim Priced at: $18.00 1.222M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi Priced at: $10.50 17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.55 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer Priced at: $8.00 7.88M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright Priced at: $8.00 4.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel Priced at: $29.00 6.897M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans Priced at: $21.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson Priced at: $41.00 4.95M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DGII X DGII Digi International Secondary Managers: Piper Sandler Priced at: $19.50 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton Priced at: $27.50 10.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VICI X VICI VICI Properties Secondary Managers: Morgan Stanley, BofA, Citi & Deutsche Bank Priced at: $29.00 60M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DX X DX Dynex Capital Spot Secondary Managers: JPMorgan & JMP Securities Priced at: $18.35 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	EYE X EYE National Vision Block Trade Managers: JPMorgan $46.50-47.00 3.9M Shares AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC $27.97 2.5M Shares FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LASR X LASR nLight Spot Secondary Managers: Stifel & Raymond James $34.00-35.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RADA X RADA Rada Electronic Spot Secondary Managers: Jefferies, Baird & Canaccord, AGPR $11.50-11.75 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial STX X STX Seagate Spot Secondary Managers: JPMorgan $75.94 4.65M Shares
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham $35.91 4M Shares
Fri	No deals

View All Syndicate Announcements »

Document Security 6.67M share Spot Secondary priced at $3.60

TODAY'S FREE FLY STORIES

Get Full Fly Access